BOTOX® – Allergan [European Edition]

BOTOX® – Botulinum Toxin Type A [European Edition, Allergan] | Gold Standard for Neuromodulator Research

Product Overview

BOTOX®, developed by Allergan (an AbbVie company), is the world’s most recognized Botulinum Toxin Type A product, widely used in clinical, therapeutic, and aesthetic applications. The European Edition of BOTOX® is manufactured under EMA-compliant GMP standards and is available in select countries for authorized distribution.

This listing is for research use only (RUO) purposes. The product is intended for non-clinical, laboratory-based applications such as neuromuscular mechanism studies, facial movement inhibition research, and anti-aging model development. With proven consistency, unmatched clinical documentation, and global brand credibility, BOTOX® remains the benchmark toxin in botulinum research.

---

Key Features & Advantages

• ✅ Manufactured by Allergan (AbbVie)
  Produced in Europe under strict GMP and quality control, with global regulatory compliance.

• ✅ Highest Clinical Reputation
  Gold standard botulinum toxin with decades of clinical and experimental documentation.

• ✅ Proven Potency and Stability
  Rapid onset (within 24–72 hours) and durable effects lasting up to 3–4 months in neuromuscular models.

• ✅ Validated in Thousands of Studies
  Extensively researched in both medical and scientific literature – ideal for data-driven comparative testing.

• ✅ Trusted Reference Toxin
  Used as a baseline in most scientific publications and regulatory submissions involving Botulinum Toxin Type A.

---

Product Specifications

• Product Name: BOTOX® – Botulinum Toxin Type A (European Edition)

• Manufacturer: Allergan plc (now part of AbbVie)

• Form: Lyophilized powder

• Strength: 100 Units / vial

• Appearance: White powder; clear, colorless solution after reconstitution

• Origin: Europe

• Storage: Store refrigerated at 2°C–8°C; reconstituted solution should be used within 24 hours

• Use Classification: For Research Use Only (RUO) – not for human or animal injection, therapy, or diagnosis

---

How It Works – Mechanism of Action

BOTOX® functions by blocking cholinergic transmission at the neuromuscular junction. Once injected into the target tissue, it binds to presynaptic nerve terminals and is internalized. Inside the nerve terminal, the light chain of the toxin cleaves the SNAP-25 protein, a critical component of the SNARE complex responsible for acetylcholine release.

This disruption inhibits signal transmission, leading to localized muscle paralysis or relaxation. In research contexts, this mechanism is highly relevant for modeling dynamic wrinkle reduction, muscular hyperactivity, chronic pain, and aesthetic symmetry analysis.

For reference, see the original mechanism explained via NIH Open Access Review.

---

Applications in Research

• Neuromuscular inhibition modeling

• Facial movement and wrinkle pathway studies

• Anti-aging and muscle-relaxation compound comparison

• Mechanistic studies on SNAP-25 protein function

• Gold-standard reference in botulinum toxin potency assays

---

Compliance Statement

This product is manufactured by Allergan (AbbVie) in Europe and distributed under applicable regulatory controls. The version offered here is labeled and provided strictly for research use only (RUO). It is not for human or veterinary use, therapeutic injection, or cosmetic procedures. Researchers must follow local biosafety and handling guidelines.

---

Tags / Keywords

BOTOX®, Allergan Botulinum Toxin, European BOTOX, Type A Toxin, Botulinum Toxin Reference Standard, SNAP-25 Research, Neuromodulator, RUO Botulinum, Anti-Aging Mechanism, AbbVie BOTOX, Facial Muscle Relaxation

---

External References

• Official BOTOX® Product Page – AbbVie

• NIH: Mechanism of Action of Botulinum Toxins

• EMA Public Assessment Report – BOTOX®